Connect your AI

Phibro Animal Health PAHC Stock-Based Comp

Stock-Based Comp at other companies

Merck & Co.MRK

$185M-5.1%

ZoetisZTS

$25M+47.1%

Elanco Animal Health Inc.ELAN

$21M+40.0%

NeogenNEOG

$1.1M-73.8%

BalchemBCPC

$5.36M+40.6%

Mirum Pharmaceuticals, Inc.MIRM

$36.2M+129%

Other financials

Income statement

Revenue$383.5M+10.3%

Gross profit$125.7M+20.2%

Operating income$44.7M+33.2%

Net income$24.0M+15.1%

EPS (diluted)$0.59+15.7%

Balance sheet

Cash & equivalents$54.9M-9.0%

Total debt$32.3M+27.8%

Total equity$361.8M+36.0%

Total assets$1.4B+9.7%

Cash flow

Operating cash flow$16.2M-62.4%

CapEx$15.3M+97.7%

Free cash flow$890.0K-97.5%

Valuation

Market cap$1.27B+31.4%

Enterprise value$1.25B+33.9%

P/E13.4×-17.1×

P/S0.9×0.0×

Profitability

Gross margin32.5%+0.9pp

Operating margin12%+4.0pp

Net margin6.3%+3.7pp

FCF margin0.9%-3.3pp

Returns & leverage

Return on equity30.3%+18.5pp

Debt / equity0.1×0.0×

Current ratio3.2×+0.3×

Where this comes from

Reported directly by Phibro Animal Health in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Phibro Animal Health's stock-based comp?: Phibro Animal Health (PAHC) reported stock-based comp of $411K in Q1 2026.
How has Phibro Animal Health's stock-based comp changed year-over-year?: Phibro Animal Health's stock-based comp increased by 129.6% year-over-year, from $179K to $411K.
What is the long-term trend for Phibro Animal Health's stock-based comp?: Over 2 years (2021 to 2025), Phibro Animal Health's stock-based comp has grown at a -20.3% compound annual growth rate (CAGR), from $1.13M to $717K.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.